PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.
Noninvasive tests (NITs) have been developed as an alternative to invasive liver biopsy, the current gold standard for non-alcoholic steatohepatitis (NASH) diagnosis and hepatic fibrosis stage identification. The use of NITs in clinical practice should facilitate the early diagnosis of high-risk non-alcoholic fatty liver disease (NAFLD).
Clinical recommendations for patients with atrial fibrillation (AF) advise radiofrequency catheter ablation (RFCA) for symptom management and cardiovascular outcome improvement. However, approximately 50% of AF patients are affected by recurrent arrhythmia within 5 years of RFCA.
Non-alcoholic fatty liver disease (NAFLD) has recently been regarded as a hepatic manifestation of metabolic syndrome (MetS) due to its similarities in aetiology with diabetes mellitus, obesity, and dyslipidaemia. Several studies in recent years have suggested that exposure toxic environmental compounds may contribute to liver disease onset.
Only a limited amount of data exists regarding the association between body mass index (BMI), non-alcoholic fatty liver disease (NAFLD), and adverse outcomes. It is known that obesity is a significant risk factor for NAFLD and its associated intra- and extrahepatic complications.
It is known that NAFLD is associated with intra- and extra-hepatic complications, including increased risk of cardiovascular disease (CVD) and chronic kidney disease. Emerging evidence has also suggested the existence of an association between NAFLD and depression.
Nonalcoholic fatty liver disease (NAFLD) is characterised by the presence of hepatic
steatosis without significant alcohol consumption or concomitant liver disease. Cardiovascular disease (CVD) is a leading cause of death in people living with NAFLD.
Transient elastography (TE) is a non-invasive, cost-efficient, and observer-independent approach to reliably detect fibrosis and steatosis. To estimate liver fibrosis, TE uses Liver Stiffness Measurement (LSM), while Controlled Attenuation Parameter (CAP) is used to assess the percentage of liver fat.
Patients with non-alcoholic fatty liver disease (NAFLD) are at a higher risk of developing liver-related complications. This includes liver decompensation and hepatocellular carcinoma (HCC).
Although this association is well-known, no comprehensive meta-analysis comparing the clinical presentation and outcomes of NAFLD-related HCC to that of non-NAFLD-related HCC currently exists.
Non-alcoholic liver disease (NAFLD)’s current nomenclature supports an exclusionary diagnosis, i.e. based on the ruling out of other liver disease causes instead of active case-finding. As an alternative to NAFLD, an international panel of experts has recently proposed a new definition of NAFLD, termed metabolic dysfunction-associated fatty liver disease (MAFLD), based on active identification of its associated metabolic risk factors.
Nonalcoholic fatty liver disease (NAFLD) is characterised by the presence of hepatic steatosis without significant alcohol consumption or concomitant liver disease. Patients with NAFLD-related cirrhosis are at a high risk of developing liver complications, including hepatocellular carcinoma (HCC).
Nonalcoholic fatty liver disease (NAFLD) refers to the development of hepatic steatosis in the absence of secondary causes. Contrarily to nonalcoholic steatohepatitis (NASH), which refers to inflammation and ballooning with or without fibrosis, NAFLD involves all histopathological changes.
The systemic immune-inflammation index (SII) is an integrated biomarker which may indicate systemic inflammation and local immune responses in the whole human body.